Cite
HARVARD Citation
Suh, C. et al. (n.d.). SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results. Annals of the rheumatic diseases. pp. 824-825. [Online].